Therapeutic targeting of tumour myeloid cells

ST Barry, DI Gabrilovich, OJ Sansom… - Nature Reviews …, 2023 - nature.com
Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance

Z Guo, M Ashrafizadeh, W Zhang, R Zou… - Cancer and metastasis …, 2024 - Springer
The metastasis is a multistep process in which a small proportion of cancer cells are
detached from the colony to enter into blood cells for obtaining a new place for metastasis …

Targeting PI3K/AKT/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects

S Stanciu, F Ionita-Radu, C Stefani, D Miricescu… - International journal of …, 2022 - mdpi.com
Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to
its low incidence, it may become in the future one of the leading causes of cancer death …

Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment

YH Zhu, JH Zheng, QY Jia, ZH Duan, HF Yao, J Yang… - Cellular Oncology, 2023 - Springer
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress

S Mehra, N Deshpande, N Nagathihalli - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic cancer has a dismal 5-year survival rate of 10%, making it one
of the deadliest forms of malignancy. The poor prognosis associated with this disease is …

Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular

O Li, L Li, Y Sheng, K Ke, J Wu, Y Mou, M Liu, W ** - Cancer Letters, 2023 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a highly life-threatening tumour with a low
early-detection rate, rapid progression and a tendency to develop resistance to …

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

K Liu, Y Geng, L Wang, H Xu, M Zou, Y Li… - Molecular …, 2022 - Wiley Online Library
Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal
adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine …

Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis

Z Tian, Y Tan, X Lin, M Su, L Pan, L Lin, G Ou… - Translational …, 2023 - Elsevier
Gemcitabine (GEM) is the first-line medication for pancreatic ductal adenocarcinoma
(PDAC). However, over some treatment cycles, GEM sensitivity declines and …

Targeting class I-II-III PI3Ks in cancer therapy: recent advances in tumor biology and preclinical research

B Thibault, F Ramos-Delgado, J Guillermet-Guibert - Cancers, 2023 - mdpi.com
Simple Summary The PI3K/AKT pathway is one of the most important signaling nodes in
cancer. While class I PI3K roles in cancer are well known, class II and III functions in …

Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer

J Guillot, C Dominici, A Lucchesi, HTT Nguyen… - Nature …, 2022 - nature.com
Neuronal nerve processes in the tumor microenvironment were highlighted recently.
However, the origin of intra-tumoral nerves remains poorly known, in part because of …